术前白细胞衍生性指标对肝癌介入术后早期复发的预测价值研究

doi:10.3969/j.issn.1006-6233.2024.09.027

摘要
图/表
参考文献
相关文章 (8)

全文: PDF (1274 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析术前白细胞衍生性指标对肝癌介入术后早期复发的预测价值。方法: 将2020年1月至2023年1月于本院行肝癌介入术的216例患者纳为研究对象,术后对其进行为期1年的随访,依据其复发情况将其分为复发组(n=110)和未复发组(n=106)。所有研究对象均在术前测定白细胞衍生指标,包括中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和淋巴细胞与单核细胞比值(LMR),以受试者工作特征曲线(ROC)分析术前NLR、PLR及LMR水平对肝癌介入术后早期复发的预测价值。结果: 复发组的术前NLR、PLR水平高于未复发组,LMR水平低于未复发组(P<0.05)。ROC曲线分析结果显示,术前NLR、PLR及LMR水平联合预测肝癌介入术后早期复发的曲线下面积(AUC)为0.958,灵敏度为82.73%,特异性为95.28%,联合预测效能优于各指标单独预测(P<0.05)。结论: 术前白细胞衍生性指标与肝癌介入术后早期复发密切相关,术前测定NLR、PLR及LMR水平可预测肝癌介入术后的早期复发情况,为指导临床治疗提供一定的参考依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈恕
	吉九威
	刘晓宇
	冯立

关键词 ：肝癌介入术, 中性粒细胞与淋巴细胞比值, 血小板与淋巴细胞比值, 淋巴细胞与单核细胞比值

Abstract：Objective: To analyze the predictive value of preoperative leukocyte-derived indicators on early recurrence of liver cancer after interventional surgery.Methods: Totally 216 patients who underwent interventional surgery for liver cancer in the hospital were included in the study from January 2020 to January 2023. They were followed up for 1 year after surgery and were divided into a recurrence group (n=110) and a non-recurrence group (n=106) according to the recurrence status. Leukocyte-derived indicators of all study subjects were measured before surgery, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR). Subject operating characteristic curve (ROC) was performed to analyze the predictive value of preoperative levels of NLR, PLR, and LMR on early recurrence after interventional surgery for liver cancer.Results: The preoperative NLR and PLR levels in the recurrence group were higher than those in the non-recurrence group while the LMR level was lower than in the non-recurrence group (P<0.05). ROC curve analysis results showed that the area under the curve (AUC) of a combination of preoperative NLR, PLR, and LMR in predicting early recurrence after liver cancer interventional surgery was 0.958, with a sensitivity of 82.73% and a specificity of 95.28%. The efficiency of combined prediction was better than that of each indicator (P<0.05). Conclusion: Preoperative leukocyte-derived indicators are closely related to early recurrence of liver cancer after interventional surgery. Preoperative measurement of NLR, PLR, and LMR levels can predict early recurrence after liver cancer interventional surgery, and provide a certain reference basis for guiding clinical treatment.

Key words： Hepatocellular carcinoma intervention Neutrophil-to-lymphocyte ratio Platelet-to-lymphocyte ratio Lymphocyte-to-monocyte ratio

基金资助:2022年度自治区卫生健康科技计划项目,(编号:202202222);内蒙古医科大学青年项目,(编号:YKD2022QN042)

通讯作者: 冯立

引用本文:

陈恕, 吉九威, 刘晓宇, 冯立. 术前白细胞衍生性指标对肝癌介入术后早期复发的预测价值研究[J]. 河北医学, 2024, 30(9): 1555-1559.
CHEN Shu, JI Jiuwei, LIU Xiaoyu, et al. A Study on the Predictive Value of Preoperative Leukocyte Derivativeness Index for Early Recurrence after Hepatocellular Carcinoma Intervention. HeBei Med, 2024, 30(9): 1555-1559.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2024.09.027 或 http://www.hbyxzzs.cn/CN/Y2024/V30/I9/1555

[1] Cheng K,Cai N,Zhu J,et al.Tumor-associated macrophages in liver cancer:from mechanisms to therapy[J].Cancer Commun (Lond),2022,42(11):1112-1140.
[2] Wu S,Fan K,Yang Q,et al.Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer:state of the art[J].Nanobiotechnology,2023,21(1):42-53.
[3] Banna GL,Friedlaender A,Tagliamento M,et al.Biological rationale for peripheral blood cell-derived inflammatory indices and related prognostic scores in patients with advanced non-small-cell lung cancer[J].Curr Oncol Rep,2022,24(12):1851-1862.
[4] Hirahara N,Matsubara T,Kaji S,et al.Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer[J].Oncotarget,2023,14:71-82.
[5] 中国抗癌协会肝癌专业委员会(CSLC),中国抗癌协会临床肿瘤学协作专业委员会(CSCO),中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].肝脏,2009,14(3):237-245.
[6] 郭飞宇,熊书名,高森,等.肿瘤组织VEGF、CD34表达联合LSM水平预测肝癌患者术后复发的价值[J].中国现代医学杂志,2023,33(16):13-19.
[7] 乔曦,许世豪,王宇炜,等.大柴胡汤通过调控p38 MAPK/IL-6/STAT3信号通路抑制肝癌的作用机制[J].中国实验方剂学杂志,2022,28(16):19-28.
[8] 沈亚伟,刘凯,吕军.术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值对UAE患者术后疼痛的预测价值[J].介入放射学杂志,2023,32(10):992-995.
[9] 陈荧野,陈勇,姜庆,等.NLR及PLR对晚期尿路上皮癌免疫治疗疗效和预后的预测价值[J].重庆医科大学学报,2023,48(8):965-970.
[10] 罗俊峰,胡军,李包根,等.基于炎症反应评分系统构建胃癌患者预后的列线图预测模型[J].中国肿瘤生物治疗杂志,2023,30(10):902-907.
[11] Song S,Bai M,Li X,et al.Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma[J].Expert Rev Mol Diagn,2022,22(3):361-378.
[12] Sugama Y,Miyanishi K,Osuga T,et al.Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy[J].JGH Open,2021,5(12):1335-1343.
[13] 秦巧莲.中性粒细胞/淋巴细胞比值、单核细胞/淋巴细胞比值及红细胞分布宽度对肝癌患者入院90d死亡率的预测价值[J].中国卫生检验杂志,2022,32(3):271-276.
[14] Minici R,Siciliano MA,Ammendola M,et al.Prognostic role of neutrophil-to-lymphocyte ratio (NLR),lymphocyte-to-monocyte ratio (LMR),platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver:the unexplored corner linking tumor microenvironment,biomarkers and interventional radiology[J].Cancers (Basel),2022,15(1):257-272.